Rigel Pharmaceuticals Inc (RIGL) - Total Liabilities
Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) has total liabilities worth $104.71 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rigel Pharmaceuticals Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Rigel Pharmaceuticals Inc (RIGL) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Rigel Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Rigel Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZYF Lopsking Aluminum Co Ltd
SHE:002333
|
China | CN¥1.00 Billion |
|
Texmaco Rail & Engineering Limited
NSE:TEXRAIL
|
India | Rs26.42 Billion |
|
Zhejiang Hengwei Battery Co. Ltd.
SHE:301222
|
China | CN¥116.29 Million |
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
South Africa | ZAC9.51 Billion |
|
Daeduck Co. Ltd.
KO:008060
|
Korea | ₩338.17 Billion |
|
MediaAlpha Inc.
NYSE:MAX
|
USA | $396.81 Million |
|
Nexen Tire
KO:002350
|
Korea | ₩2.95 Trillion |
|
Origin Enterprises Plc
IR:OIZ
|
Ireland | €987.05 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Rigel Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Rigel Pharmaceuticals Inc (RIGL) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rigel Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual total liabilities of Rigel Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $122.11 Million | -24.01% |
| 2024-12-31 | $160.69 Million | +10.16% |
| 2023-12-31 | $145.87 Million | -1.37% |
| 2022-12-31 | $147.90 Million | +7.99% |
| 2021-12-31 | $136.95 Million | +79.37% |
| 2020-12-31 | $76.35 Million | -18.56% |
| 2019-12-31 | $93.75 Million | +220.72% |
| 2018-12-31 | $29.23 Million | +58.31% |
| 2017-12-31 | $18.46 Million | -20.09% |
| 2016-12-31 | $23.11 Million | -42.76% |
| 2015-12-31 | $40.37 Million | +55.92% |
| 2014-12-31 | $25.89 Million | +45.39% |
| 2013-12-31 | $17.81 Million | -14.99% |
| 2012-12-31 | $20.95 Million | -0.05% |
| 2011-12-31 | $20.96 Million | +1.91% |
| 2010-12-31 | $20.56 Million | -33.40% |
| 2009-12-31 | $30.88 Million | -22.21% |
| 2008-12-31 | $39.69 Million | +18.11% |
| 2007-12-31 | $33.61 Million | +29.20% |
| 2006-12-31 | $26.01 Million | -33.44% |
| 2005-12-31 | $39.08 Million | +47.35% |
| 2004-12-31 | $26.52 Million | +70.54% |
| 2003-12-31 | $15.55 Million | -17.72% |
| 2002-12-31 | $18.90 Million | +7.96% |
| 2001-12-31 | $17.51 Million | +14.78% |
| 2000-12-31 | $15.25 Million | -7.07% |
| 1999-12-31 | $16.41 Million | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more